The tablets have an estimated market size of US $ 548 million for twelve months ending December 2021 according to IQVIA
A total of three targets have been selected for portfolio entry in the collaboration to date, with the potential to generate further future development milestones and sales-based royalty revenues for BenevolentAI
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
Four additional AT2R agonists are expected to finalize preclinical evaluation during 2022
_256_384.jpg)
India registers 18% of deaths annually due to air pollution while seven million die annually across the world due to air pollution
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
